Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer

Abstract Background Concurrent chemoradiotherapy (CCRT) followed by durvalumab is the standard of care for unresectable locally-advanced non-small cell carcinoma (LA-NSCLC). However, a major concern about administration of durvalumab after CCRT is whether the incidence of symptomatic radiation pneum...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Hiroshi Mayahara, Kazuyuki Uehara, Aya Harada, Keiji Kitatani, Tomonori Yabuuchi, Shuichirou Miyazaki, Takeaki Ishihara, Hiroki Kawaguchi, Hikaru Kubota, Hideaki Okada, Taira Ninomaru, Chihiro Shindo, Akito Hata
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	BMC 2022-01-01
سلاسل:	Radiation Oncology
الموضوعات:	Locally advanced non-small cell lung cancer Concurrent chemoradiotherapy Radiation pneumonitis Dosimetric factor Durvalumab
الوصول للمادة أونلاين:	https://doi.org/10.1186/s13014-021-01979-z
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!